Nuclear Medicine Imaging of Lung Cancer and Esophagus Cancer

AKADEMISK AVHANDLING
som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i Föreläsningssal C1-87, Karolinska Universitetssjukhuset, Huddinge

Fredagen den 23 september 2011, kl 09.00

av

Gunnar Herlin
Leg.läkare

Huvudhandledare:
Docent Rimma Axelsson
Karolinska Institutet
Institutionen för klinisk vetenskap, intervention och teknik
Enheten för medicinsk bild, funktion och teknologi

Fakultetsopponent:
Professor Anders Sundin
Karolinska Institutet
Institutionen för molekylär medicin och kirurgi
Enheten för diagnostisk radiologi

Bihandledare:
Professor Lars Lundell
Karolinska Institutet
Institutionen för klinisk vetenskap, intervention och teknik
Enheten för kirurgi

Betygsnämnd:
Docent Jens Sörensen
Uppsala universitet
Institutionen för radiologi, onkologi och strälningsvetenskap
Enheten för nuklearmedicin och PET

Med dr Karl-Gustaf Kölbeck
Karolinska Institutet
Institutionen för medicin, Solna
Enheten för lungmedicin

Professor Heikki Minn
University of Turku
Department of Oncology and Radiotherapy

Docent Gunnar Hillerdal
Karolinska Institutet
Institutionen för medicin, Solna
Enheten för lungmedicin

Stockholm 2011
ABSTRACT

Background: Somatostatin receptors (SSTRs) occur in cancer tissue, and $^{99m}$Tc-depreotide is a labelled somatostatin receptor analogue, binding to SSTRs subtype 2, 3, and 5.

Purpose: The general aim of the present thesis was to study somatostatin receptor scintigraphy (SSTRS) with $^{99m}$Tc-depreotide in the diagnosis and characterization of cancers in the lung and oesophagus.

Study I evaluated the diagnostic value of the SSTRS with $^{99m}$Tc-depreotide in 99 patients with suspected lung cancer. The sensitivity to detect malignancy was 94%, and to detect lung cancer 98%. The specificity was calculated on two sets of data. When all cases are used, the specificity was 52%. If the 12 pneumonias are excluded, the specificity was 77%.

Study II was performed on 19 patients with histologically proven non-small-cell lung cancer (NSCLC), where the expression of SSTR subtype 2 was looked for and found by immunohistochemical methods. The quantitative evaluation of $^{99m}$Tc-depreotide was performed using region-of-interest analysis and includes tumour counts/cm$^3$, background counts/cm$^3$, and the ratio between tumour and background counts. SSTR subtype 2 expression was positively correlated to the degree of the tumour’s differentiation ($p < 0.05$). $^{99m}$Tc-depreotide uptake in tumour cells did not correlate with tumour grade or SSTR subtype 2, MIB-1, or p53 expression.

Study III showed the feasibility of imaging oesophageal carcinoma with SSTRS with $^{99m}$Tc-depreotide and optimal time intervals for imaging. None of the 13 cancer-free Barrett’s oesophagus patients in this study showed an increased $^{99m}$Tc-depreotide uptake.

Study IV investigated the expression of SSTRs of subtype 2A, 2B, 3, and 5 in 28 patients with suspected oesophageal cancer, where expression was detected in small amount in adenocarcinoma and was absent in squamous cell carcinoma. There was no correlation between the $^{99m}$Tc-depreotide uptake and the amount of SSTRs, and no correlation between the amount of SSTRs and the differentiation grade of the tumour.

Conclusion: SSTRS with the labeled somatostatin receptor analogue $^{99m}$Tc-depreotide has a very high sensitivity for detecting lung cancer. A negative scintigraphy strongly suggests a benign lesion, and the method is useful in decision making with respect to surgery.

There is an expression of SSTRS subtype 2 in NSCLC with a positive correlation between tumour differentiation and presence of SSTR subtype 2. There is no correlation between $^{99m}$Tc-depreotide uptake compared to tumour differentiation, presence of SSTR subtype 2, p53, or MIB-1, and SSTRS cannot be used as a prognostic factor in patients with lung cancer.

SSTRS with $^{99m}$Tc-depreotide of oesophageal cancer is feasible, but not suitable, for either screening or primary diagnosis, because of the method’s modest sensitivity. However, this method has a high specificity. The majority of patients with adenocancer of the oesophagus have a low amount of SSTRs, while most of the patients with squamous cell cancer do not have any of SSTRs.

© Gunnar Herlin, 2011
ISBN 978-91-7457-403-6